Matthew Galsky

Department of Hematology/Oncology, Icahn School of Medicine at Mount Sinai

Affiliated withIcahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai

Research Area

Biography

Matthew Galsky has not added Biography.
If you are Matthew Galsky and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 59	2015

Other Publications

Article	Year
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic pros... Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 15735119	2005
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)? Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 15939919	2005
Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16033836	2005
The role of taxanes in the management of bladder cancer. The oncologist\| PubMed ID: 16314289	2005
A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (B... Cancer\| PubMed ID: 16329138	2006
Violaceous exanthem as a manifestation of metastatic prostate cancer in skin. Urology\| PubMed ID: 16461102	2006
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer\| PubMed ID: 16773629	2006
Problems with the randomized discontinuation design. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 17008711	2006
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Investigational new drugs\| PubMed ID: 17146733	2007
Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer\| PubMed ID: 17200962	2007
Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. Clinical genitourinary cancer\| PubMed ID: 17239282	2006
High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care? Nature clinical practice. Urology\| PubMed ID: 17297500	2007
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology\| PubMed ID: 17320659	2007
Outcomes and prognosis in advanced renal cell carcinoma. Expert review of anticancer therapy\| PubMed ID: 17555394	2007
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer\| PubMed ID: 17941029	2007
Germ-cell tumors. The New England journal of medicine\| PubMed ID: 17969229	2007
Novel agents for muscle-invasive and advanced urothelial cancer. BJU international\| PubMed ID: 18005203	2008
Current optimal chemotherapy for advanced urothelial cancer. Expert review of anticancer therapy\| PubMed ID: 18095883	2008
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18362364	2008
Trial design for metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18640946	2008
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Investigational new drugs\| PubMed ID: 19262991	2010
Patient selection for phase II trials. American journal of clinical oncology\| PubMed ID: 19346816	2009
Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest\| PubMed ID: 19349386	2009
The integration of chemotherapy and surgery for bladder cancer. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 19813322	2005
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. Urologic oncology\| PubMed ID: 19959380	2011
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 20159797	2010
Bladder cancer: advances in treatment and research. Clinical advances in hematology & oncology : H&O\| PubMed ID: 20505645	2010
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. The Lancet. Oncology\| PubMed ID: 20537950	2010
First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients? Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 20644092	2010
Cabazitaxel. Nature reviews. Drug discovery\| PubMed ID: 20811375	2010
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Investigational new drugs\| PubMed ID: 20857170	2012
Bladder cancer: current management and opportunities for a personalized approach. The Mount Sinai journal of medicine, New York\| PubMed ID: 21105122	2010
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 21135284	2011
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. The Lancet. Oncology\| PubMed ID: 21376284	2011
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 21555688	2011
Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Clinical Medicine Insights. Oncology\| PubMed ID: 21695098	2011
Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clinical genitourinary cancer\| PubMed ID: 21700509	2011
Role of American Society of Clinical Oncology in low- and middle-income countries. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 21709190	2011
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology\| PubMed ID: 21762967	2011
Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clinical genitourinary cancer\| PubMed ID: 22130294	2012
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer\| PubMed ID: 22282219	2012
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research. Urologic oncology\| PubMed ID: 22300756	2013
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant pro... Clinical genitourinary cancer\| PubMed ID: 22340631	2012
Editorial comment. The Journal of urology\| PubMed ID: 22425108	2012
Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status. American journal of clinical oncology\| PubMed ID: 22433994	2012
Overcoming castration resistance in prostate cancer. Current opinion in urology\| PubMed ID: 22472508	2012
Novel molecular targets for the therapy of urothelial carcinoma. Expert opinion on therapeutic targets\| PubMed ID: 22510032	2012
The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies. Urologic oncology\| PubMed ID: 22513137	2013
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU international\| PubMed ID: 22520631	2012
Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. CA: a cancer journal for clinicians\| PubMed ID: 22535487	2012
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. Urologic oncology\| PubMed ID: 22552048	2013
The emerging role of circulating tumor cell detection in genitourinary cancer. The Journal of urology\| PubMed ID: 22578722	2012
Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World journal of urology\| PubMed ID: 22622394	2013
Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer treatment reviews\| PubMed ID: 22651902	2012
Trends in the use of cytoreductive nephrectomy in the United States. Clinical genitourinary cancer\| PubMed ID: 22651971	2012
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. The Journal of clinical investigation\| PubMed ID: 22653055	2012
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. European urology\| PubMed ID: 22677572	2012
Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit? The Journal of urology\| PubMed ID: 22704119	2012
Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer\| PubMed ID: 22707387	2012
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PloS one\| PubMed ID: 22761653	2012
Antiangiogenic treatment in metastatic urothelial cancer. The Lancet. Oncology\| PubMed ID: 22819171	2012
Editorial comment. The Journal of urology\| PubMed ID: 22901587	2012
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. European urology\| PubMed ID: 22917984	2013
Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU international\| PubMed ID: 22985411	2012
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Clinical genitourinary cancer\| PubMed ID: 23000202	2012
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The Lancet. Oncology\| PubMed ID: 23059047	2012
Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. Journal of the National Cancer Institute\| PubMed ID: 23093559	2012
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 23150697	2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. European urology\| PubMed ID: 23206856	2013
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World journal of urology\| PubMed ID: 23223962	2013
Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer. Clinical genitourinary cancer\| PubMed ID: 23228446	2012
Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert review of anticancer therapy\| PubMed ID: 23253220	2012
A prognostic model for metastatic renal-cell carcinoma. The Lancet. Oncology\| PubMed ID: 23312462	2013
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Critical reviews in oncology/hematology\| PubMed ID: 23317774	2013
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clinical genitourinary cancer\| PubMed ID: 23332638	2013
Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urologic oncology\| PubMed ID: 23428534	2014
Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis. Cancer treatment reviews\| PubMed ID: 23455076	2013
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer\| PubMed ID: 23456777	2013
Metabolic and toxicological considerations of newly approved prostate cancer drugs. Expert opinion on drug metabolism & toxicology\| PubMed ID: 23581700	2013
Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches. Clinical advances in hematology & oncology : H&O\| PubMed ID: 23598909	2013
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. European urology\| PubMed ID: 23628492	2013
The impact of gender on outcomes in patients with metastatic urothelial carcinoma. Clinical genitourinary cancer\| PubMed ID: 23673281	2013
Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer treatment reviews\| PubMed ID: 23684373	2014
Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urologic oncology\| PubMed ID: 23685020	2014
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer. European urology\| PubMed ID: 23706567	2014
A new approach to second-line therapy for urothelial cancer? The Lancet. Oncology\| PubMed ID: 23706984	2013
Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. Cancer\| PubMed ID: 23720197	2013
Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer\| PubMed ID: 23720216	2013
Tumour angiogenesis: an elusive target in castration-resistant prostate cancer. The Lancet. Oncology\| PubMed ID: 23742876	2013
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clinical genitourinary cancer\| PubMed ID: 23800847	2013
Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clinical genitourinary cancer\| PubMed ID: 23816526	2013
Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis. Critical reviews in oncology/hematology\| PubMed ID: 23830806	2013
Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Targeted oncology\| PubMed ID: 23852656	2014
Metastatic renal cancer: better never than late. European urology\| PubMed ID: 23954087	2014
Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urologic oncology\| PubMed ID: 24055428	2014
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU international\| PubMed ID: 24219029	2014
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clinical genitourinary cancer\| PubMed ID: 24220220	2014
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU international\| PubMed ID: 24298897	2014
Adverse event reporting in cancer clinical trial publications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 24323037	2014
Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. Urologic oncology\| PubMed ID: 24332646	2014
Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. Clinical genitourinary cancer\| PubMed ID: 24355418	2014
Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resis... European urology\| PubMed ID: 24433812	2014
New developments in urothelial cancer. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting\| PubMed ID: 24451754	2012
Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. Critical reviews in oncology/hematology\| PubMed ID: 24500033	2014
Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of r... Cancer treatment reviews\| PubMed ID: 24629273	2014
Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better? European urology\| PubMed ID: 24631407	2014
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24727324	2014
T2 muscle-invasive bladder cancer. Seminars in oncology\| PubMed ID: 24787300	2014
Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. American journal of clinical oncology\| PubMed ID: 24824144	2014
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. European urology\| PubMed ID: 24841777	2015
Current approaches to the management of bladder cancer in older patients. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting\| PubMed ID: 24857110	2014
Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics. Cancer\| PubMed ID: 24965362	2014
New drugs and treatment strategies in prostate cancer. Clinical advances in hematology & oncology : H&O\| PubMed ID: 25000316	2014
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer chemotherapy and pharmacology\| PubMed ID: 25023489	2014
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clinical genitourinary cancer\| PubMed ID: 25035282	2014
Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). BJU international\| PubMed ID: 25046451	2015
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. The oncologist\| PubMed ID: 25052451	2014
Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urologic oncology\| PubMed ID: 25065704	2015
Rethinking cancer clinical trials for the future. Future oncology (London, England)\| PubMed ID: 25145425	2014
Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology\| PubMed ID: 25150635	2014
Adult cancer clinical trials that fail to complete: an epidemic? Journal of the National Cancer Institute\| PubMed ID: 25190726	2014
Use of crowdsourcing for cancer clinical trial development. Journal of the National Cancer Institute\| PubMed ID: 25217580	2014
Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology? European urology\| PubMed ID: 25220371	2015
Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer. Cancer\| PubMed ID: 25302607	2014
Biomarkers for bladder cancer management: present and future. American journal of clinical and experimental urology\| PubMed ID: 25374904	2014
Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA internal medicine\| PubMed ID: 25437434	2015
Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 25453078	2014
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clinical genitourinary cancer\| PubMed ID: 25458370	2015
How I treat bladder cancer in elderly patients. Journal of geriatric oncology\| PubMed ID: 25482022	2015
Survival of patients with stage IV lung cancer with diabetes treated with metformin. American journal of respiratory and critical care medicine\| PubMed ID: 25522257	2015
Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. The Prostate\| PubMed ID: 25560638	2015
Kidney cancer: Systemic therapy--differentiating the achievable from the achieved. Nature reviews. Urology\| PubMed ID: 25600095	2015
Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. The Journal of urology\| PubMed ID: 25623747	2015
The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care. The Journal of urology\| PubMed ID: 25623748	2015
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer cell\| PubMed ID: 25670080	2015
Clinical trial awareness: Changes over time and sociodemographic disparities. Clinical trials (London, England)\| PubMed ID: 25673636	2015
First-line treatment of metastatic disease: cisplatin-ineligible patients. Hematology/oncology clinics of North America\| PubMed ID: 25836938	2015
The landscape of precision cancer medicine clinical trials in the United States. Cancer treatment reviews\| PubMed ID: 25864024	2015
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer\| PubMed ID: 25872978	2015
Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice. The Urologic clinics of North America\| PubMed ID: 25882560	2015
Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. Frontiers in oncology\| PubMed ID: 26125012	2015
Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies. Trials\| PubMed ID: 26253548	2015
A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC medicine\| PubMed ID: 26297150	2015
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urologic oncology\| PubMed ID: 26362343	2015
Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer chemotherapy and pharmacology\| PubMed ID: 26464352	2015